MINSK, 14 October (BelTA) – In H1 locally-produced medicines accounted for 68% of the Belarusian market in natural terms, Sergei Kazakevich, Director General of the Management Company of the Belpharmprom Pharmaceutical Holding Company, said at the roundtable "Belarus' pharmaceutical industry: Meeting the needs of healthcare and population" at BelTA's press center.
“We estimate our market share not only in value terms but also in natural terms, i.e. in packages, the number of drugs that people, healthcare consumed. In H1, our market share in packages stood at 68%. The share was 65% in retail, i.e. pharmacies, and 91.5% in hospitals,” Sergei Kazakevich informed.
For a number of years, Belarusian medicines have been holding an approximately 50% share of the domestic market in value terms. Such a goal was set by the head of state in the past, and it was successfully fulfilled. This figure is influenced by factors that do not depend on the efforts made by the pharmaceutical industry, Sergei Kazakevich noted. For example, a change in the exchange rate automatically entails recalculation. As a result, the figure may differ by several percents both ways.
In January-August, domestic medicines accounted for 51.5% of the Belarusian market in value terms. More than 60% of Belarusian medicines are produced by the companies affiliated with the Belpharmprom holding company. According to Sergei Kazakevich, this shows that Belarusian pharmaceutical products are in demand. The industry successfully ensures the state's pharmaceutical security.
The roundtable was dedicated to the Pharmaceutical and Microbiological Industry Workers' Day marked in Belarus on 15 October.
